Hims & Hers Health (NYSE:HIMS) Shares Up 7.1% – What’s Next?
by Michael Walen · The Markets DailyHims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares rose 7.1% during trading on Tuesday . The company traded as high as $30.92 and last traded at $31.4240. Approximately 7,191,239 shares changed hands during trading, a decline of 70% from the average daily volume of 24,206,293 shares. The stock had previously closed at $29.35.
Key Stories Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Neutral Sentiment: Investor attention around HIMS has increased substantially, with Zacks noting that the stock has become one of its most heavily searched names. Elevated attention can increase volatility but does not by itself change the company’s fundamentals. Zacks HIMS investor search article
- Negative Sentiment: Numerous law firms—including Rosen, Kaplan Fox, Hagens Berman, Robbins Geller, Faruqi & Faruqi, Bernstein Liebhard, SBS Law, Wolf Haldenstein and Glancy Prongay—are soliciting investors for a securities-fraud class action against Hims & Hers. The case covers investors who purchased shares from August 4, 2025 through July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. The repeated notices increase reputational and potential legal-liability concerns, although they largely repeat the same procedural update. Rosen HIMS securities action notice
- Negative Sentiment: The litigation stems from allegations tied to a Federal Trade Commission complaint, which reportedly accuses Hims of serious business misconduct. If claims are substantiated, the company could face financial penalties, legal costs, management distraction and pressure on customer trust. Hagens Berman HIMS class action article
- Negative Sentiment: HIMS CFO-related insider selling was also reported, involving approximately $354,861 of stock. While one transaction is not necessarily a fundamental signal, insider selling can weigh on sentiment when combined with regulatory and litigation concerns. HIMS CFO stock sale article
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on HIMS shares. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. assumed coverage on Hims & Hers Health in a research note on Friday, September 11th. They set a “neutral” rating and a $32.00 target price for the company. Citigroup lowered their target price on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Barclays dropped their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Finally, TD Cowen raised their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $32.43.
Get Our Latest Stock Report on Hims & Hers Health
Hims & Hers Health Trading Up 5.6%
The business has a 50 day moving average of $29.96 and a two-hundred day moving average of $27.78. The firm has a market capitalization of $7.23 billion, a price-to-earnings ratio of -50.05 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The company’s revenue was up 38.2% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.
Insider Buying and Selling at Hims & Hers Health
In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the completion of the sale, the chief operating officer owned 456,660 shares in the company, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 12,313 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $28.82, for a total transaction of $354,860.66. Following the transaction, the chief financial officer owned 251,804 shares in the company, valued at approximately $7,256,991.28. The trade was a 4.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 99,407 shares of company stock worth $2,855,023. 11.76% of the stock is owned by company insiders.
Hedge Funds Weigh In On Hims & Hers Health
A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after buying an additional 608,950 shares during the last quarter. Bank of America Corp DE raised its position in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System lifted its stake in Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock valued at $48,549,000 after acquiring an additional 280,900 shares in the last quarter. Norges Bank bought a new position in Hims & Hers Health during the 4th quarter valued at $62,153,000. Finally, Clear Street Group Inc. boosted its holdings in Hims & Hers Health by 23.6% during the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock worth $61,832,000 after acquiring an additional 363,893 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.
Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.
The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.